FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1810-1820 November 1, 2007 Number 18 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Cunningham, D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer.

Methods Patients in Japan with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph-node dissection were randomly assigned to undergo surgery followed by adjuvant therapy with S-1 or to undergo surgery only. In the S-1 group, administration of S-1 was started within 6 weeks after surgery and continued for 1 year. The treatment regimen consisted of 6-week cycles in which, in principle, 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks. The primary end point was overall survival.

Results We randomly assigned 529 patients to the S-1 group and 530 patients to the surgery-only group between October 2001 and December 2004. The trial was stopped on the recommendation of the independent data and safety monitoring committee, because the first interim analysis, performed 1 year after enrollment was completed, showed that the S-1 group had a higher rate of overall survival than the surgery-only group (P=0.002). Analysis of follow-up data showed that the 3-year overall survival rate was 80.1% in the S-1 group and 70.1% in the surgery-only group. The hazard ratio for death in the S-1 group, as compared with the surgery-only group, was 0.68 (95% confidence interval, 0.52 to 0.87; P=0.003). Adverse events of grade 3 or grade 4 (defined according to the Common Toxicity Criteria of the National Cancer Institute) that were relatively common in the S-1 group were anorexia (6.0%), nausea (3.7%), and diarrhea (3.1%).

Conclusions S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer. (ClinicalTrials.gov number, NCT00152217 [ClinicalTrials.gov] .)

Source Information

From Kitasato University School of Medicine, Sagamihara (S.S.); National Cancer Center Hospital (M.S.), the Cancer Institute Hospital (T.Y., T.N.), Nihon University School of Medicine (M.F.), University of Tokyo (Y.O.), and Tokyo Metropolitan Komagome Hospital (K.A.) — all in Tokyo; National Cancer Center Hospital East, Kashiwa (T.K.); Niigata Cancer Center Hospital, Niigata (A.N.); Sakai City Hospital, Sakai (H.F., H.I.); Osaka City General Hospital, Osaka (M.H.); Aichi Cancer Center Hospital, Nagoya (Y.Y.); and National Hospital Organization Shikoku Cancer Center, Matsuyama (A.K.) — all in Japan.

Address reprint requests to Dr. Sakuramoto at the Department of Surgery, Kitasato University School of Medicine, 2-1-1 Asamizodai, Sagamihara, Kanagawa 228-8520, Japan, or at sakura{at}med.kitasato-u.ac.jp.

Full Text of this Article

This article has been cited by other articles:

• BAR-SELA, G., TSALIC, M., STEINER, M., WOLLNER, M., HAIM, N. (2009). Local Recurrence following Adjuvant Chemotherapy without Radiotherapy in Completely Resected Stomach and Gastroesophageal Junction Adenocarcinoma. Anticancer Res 29: 1853-1856 [Abstract] [Full Text]  
• Jackson, C., Cunningham, D., Oliveira, J., On behalf of the ESMO Guidelines Working Group, (2009). Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv34-iv36 [Full Text]  
• FURUSE, H., HIRANO, Y., HARADA, M., MING, L. H., AOKI, T., KURITA, Y., MUGIYA, S., USHIYAMA, T., OZONO, S. (2009). Significance of 5-Fluorouracil-related Enzyme Activities in Predicting Sensitivity to 5-Fluorouracil in Bladder Carcinoma. Anticancer Res 29: 1001-1008 [Abstract] [Full Text]  
• Badruddoja, M. (2009). Total Gastrectomy. Arch Surg 144: 289-290 [Full Text]  
• Fatourou, E., Macheras, A., Misiakos, E. P., Liakakos, T. (2009). Perioperative Chemotherapy for Gastric Cancer. Ann. Surg. Oncol. 16: 226-227 [Full Text]  
• Shirasaka, T. (2009). Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas. Jpn J Clin Oncol 39: 2-15 [Abstract] [Full Text]  
• Hayashi, M., Inokuchi, M., Takagi, Y., Yamada, H., Kojima, K., Kumagai, J., Kawano, T., Sugihara, K. (2008). High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer. Clin. Cancer Res. 14: 7843-7849 [Abstract] [Full Text]  
• Ricart, A. D., Berlin, J. D., Papadopoulos, K. P., Syed, S., Drolet, D. W., Quaratino-Baker, C., Horan, J., Chick, J., Vermeulen, W., Tolcher, A. W., Rowinsky, E. K., Rothenberg, M. L. (2008). Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors. Clin. Cancer Res. 14: 7947-7955 [Abstract] [Full Text]  
• Barreto, S. G., Shukla, P. J., Ramadori, G., Triebel, J., Hundahl, S. A., Sasako, M., Kurokawa, Y., Yamamoto, S. (2008). Nodal Dissection for Gastric Cancer. NEJM 359: 2392-2393 [Full Text]  
• Shitara, K., Muro, K., Ura, T., Takahari, D., Yokota, T., Sawaki, A., Kawai, H., Ito, S., Yamamura, Y. (2008). Chemotherapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1. Jpn J Clin Oncol 38: 786-789 [Abstract] [Full Text]  
• Liakakos, T., Fatourou, E., Ziogas, D., Lykoudis, E., Roukos, D. H. (2008). Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer--Promises and Reality. Ann. Surg. Oncol. 15: 2981-2982 [Full Text]  
• Lieto, E., Ferraraccio, F., Orditura, M., Castellano, P., LaMura, A., Pinto, M., Zamboli, A., DeVita, F., Galizia, G. (2008). Integrated Therapy in Localized Gastric Cancer: Targeted and Tailored Approach. Ann. Surg. Oncol. 15: 2983-2985 [Full Text]  
• Stein, W. D., Yang, J., Bates, S. E., Fojo, T. (2008). Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage. The Oncologist 13: 1055-1062 [Abstract] [Full Text]  
• Liakakos, T., Fatourou, E. (2008). Stage-Specific Guided Adjuvant Treatment for Gastric Cancer. Ann. Surg. Oncol. 15: 2622-2623 [Full Text]  
• Sasako, M., Sano, T., Yamamoto, S., Kurokawa, Y., Nashimoto, A., Kurita, A., Hiratsuka, M., Tsujinaka, T., Kinoshita, T., Arai, K., Yamamura, Y., Okajima, K., the Japan Clinical Oncology Group, (2008). D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer. NEJM 359: 453-462 [Abstract] [Full Text]  
• Mansour, J. C., Coit, D. G. (2008). Appropriate Treatment for Patients with Gastric Adenocarcinoma. Ann. Surg. Oncol. 15: 1798-1799 [Full Text]  
• Aykan, N. F., Idelevich, E. (2008). The role of UFT in advanced gastric cancer. Ann Oncol 19: 1045-1052 [Abstract] [Full Text]  
• Khushalani, N. I. (2008). Cancer of the Esophagus and Stomach. Mayo Clin Proc. 83: 712-722 [Abstract] [Full Text]  
• Liakakos, T., Roukos, D. H. (2008). More Controversy than Ever - Challenges and Promises Towards Personalized Treatment of Gastric Cancer. Ann. Surg. Oncol. 15: 956-960 [Full Text]  
• Harissis, H., Fatouros, M. (2008). Nodal Micrometastases Status--Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer?. Ann. Surg. Oncol. 15: 1256-1257 [Full Text]  
• Di Costanzo, F., Gasperoni, S., Manzione, L., Bisagni, G., Labianca, R., Bravi, S., Cortesi, E., Carlini, P., Bracci, R., Tomao, S., Messerini, L., Arcangeli, A., Torri, V., Bilancia, D., Floriani, I., Tonato, M., On behalf of Italian Oncology Group for Cancer Res, (2008). Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. JNCI J Natl Cancer Inst 100: 388-398 [Abstract] [Full Text]  
• Wu, A., Ji, J. (2008). Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma?. JNCI J Natl Cancer Inst 100: 376-377 [Full Text]  
• Hwang, J. (2008). Resectable Esophageal, Gastroesophageal Junction, and Gastric Cancers: Therapy Is Distinct for Gastric Cancer. Am Soc Clin Oncol Ed Book 2008: 172-176 [Abstract] [Full Text]  
• Cunningham, D., Chua, Y. J. (2007). East Meets West in the Treatment of Gastric Cancer. NEJM 357: 1863-1865 [Full Text]  
• (2007). Adjuvant Chemotherapy for Gastric Cancer. JWatch Gastroenterology 2007: 1-1 [Full Text]  
• (2007). Oral Adjuvant Chemotherapy with S-1 Lengthens Survival in Gastric Cancer Patients. JWatch Oncology and Hematology 2007: 1-1 [Full Text]